Medexus Pharmaceuticals Inc.

Toronto Stock Exchange MDP.TO

Medexus Pharmaceuticals Inc. Price to Book Ratio (P/B) on January 28, 2025: 2.25

Medexus Pharmaceuticals Inc. Price to Book Ratio (P/B) is 2.25 on January 28, 2025, a 11.87% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Medexus Pharmaceuticals Inc. 52-week high Price to Book Ratio (P/B) is 2.77 on January 24, 2025, which is 22.77% above the current Price to Book Ratio (P/B).
Medexus Pharmaceuticals Inc. 52-week low Price to Book Ratio (P/B) is 0.88 on April 17, 2024, which is -60.89% below the current Price to Book Ratio (P/B).
Medexus Pharmaceuticals Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.41.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Toronto Stock Exchange: MDP.TO

Medexus Pharmaceuticals Inc.

CEO	Mr. Kenneth d'Entremont
IPO Date	Jan. 9, 2014
Location	Canada
Headquarters	35 Nixon Road
Employees	82
Sector	Health Care
Industries Pharmaceuticals

Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Key trends

Past 5 years